Optimalization and cost management of lanreotide-Autogel therapy in acromegaly
Open Access
- 1 November 2007
- journal article
- research article
- Published by Bioscientifica in Acta Endocrinologica
- Vol. 157 (5), 571-577
- https://doi.org/10.1530/eje-07-0366
Abstract
Background: Lanreotide-Autogel is a depot formulation of the somatostatin analog lanreotide used in the treatment of acromegaly. We investigated whether prolonging or shortening the interval between injections would offer any benefit.Subjects and methods: The interval was prolonged from once every 4 weeks to once every 6 weeks when patients (n=9) had normal IGF-I and GH concentrations. When patients (n=12) had still elevated IGF-I or GH on the maximal dose of 120 mg every 4 weeks, the interval was shortened to once every 3 weeks. Serum IGF-I and GH were measured after 12 and 24 weeks to allow for dose adaptation. Symptoms and tumor volume were evaluated at baseline and after 36 weeks.Results: In seven of the nine subjects with normal IGF-I and GH, the interval could be extended to 6 weeks without loosing efficacy on IGF-I (195 vs 213 μg/l; not significant, NS) and GH concentrations (1.4 vs 1.3 μg/l; NS). The weekly dose could significantly be reduced (from 23.3 to 17.8 mg; P=0.002). In only 1 of the 12 not-controlled patients, reducing the interval to once every 3 weeks induced normalization of IGF-I and GH.Conclusion: In subjects whose acromegaly is well controlled using lanreotide-Autogel, prolonging the time interval between injections can often be increased 4 to 6 weeks without loss of efficacy, thereby improving the subject's comfort and reducing the cost of treatment. On the other hand, in subjects whose acromegaly is not controlled on a dose of 120 mg every 4 weeks, reducing the interval to every 3 weeks is rarely beneficial.Keywords
This publication has 26 references indexed in Scilit:
- Is There Still a Role for Radiotherapy in Acromegaly?Neuroendocrinology, 2006
- Long-Acting Somatostatin Analog Therapy of Acromegaly: A Meta-AnalysisJournal of Clinical Endocrinology & Metabolism, 2005
- Efficacy of radiotherapy in normalizing serum IGF‐I, acid‐labile subunit (ALS) and IGFBP‐3 levels in acromegalyClinical Endocrinology, 2001
- Slow-release lanreotide in the treatment of acromegaly: a study in 66 patientsActa Endocrinologica, 2000
- Current Therapy for AcromegalyTrends in Endocrinology & Metabolism, 2000
- Outcome of Radiotherapy for Acromegaly Using Normalization of Insulin-Like Growth Factor I to Define CureJournal of Clinical Endocrinology & Metabolism, 2000
- Cabergoline in the Treatment of Acromegaly: A Study in 64 PatientsJournal of Clinical Endocrinology & Metabolism, 1998
- Treatment of prolactin-secreting macroadenomas with the once-weekly dopamine agonist cabergolineJournal of Clinical Endocrinology & Metabolism, 1996
- Effectiveness and tolerability of slow release lanreotide treatment in active acromegaly: six-month report on an Italian multicenter study. Italian Multicenter Slow Release Lanreotide Study GroupJournal of Clinical Endocrinology & Metabolism, 1996
- Depot long-acting somatostatin analog (Sandostatin-LAR) is an effective treatment for acromegalyJournal of Clinical Endocrinology & Metabolism, 1995